| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | interleukin 31 (IL-31) |
| Clinical data | |
| Trade names | Cytopoint |
| Routes of administration | subcutaneous injection |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lokivetmab, trade nameCytopoint, is amonoclonal antibody used to treatatopic dermatitis in dogs.[1] It acts againstinterleukin 31 (IL-31),[2] which is acytokine involved in causing itchiness (pruritus).[2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.[3]
TheUnited States Department of Agriculture (USDA) approved lokivetmab (manufactured byZoetis and sold under the trade name Cytopoint) in December 2016,[3] and it was approved by theEuropean Medicines Agency in 2017.[4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.[4]
 | Thisdermatologicdrug article is astub. You can help Wikipedia byadding missing information. |
